(BW)(MA-INNOCENTIVE) InnoCentive 悬赏100万美元寻找生物标记，目标是为鲁盖瑞氏症（ALS）寻找生物标记

美国商业资讯2006年11月13日马萨诸塞州ANDOVER消息――

InnoCentive今天宣布，以加速鲁盖瑞氏症研究为目的的非盈利组织Prize4Life, Inc.，提供了100万美元赏金以加速鲁盖瑞氏症治疗方法的探索。InnoCentive首席科学官Jill A. Panetta 博士说：“寻找鲁盖瑞氏症生物标记的重大挑战将帮助确定应对疾病的特定措施，从而为疗法发现和效果检测提供便利。”

医学博士Robert H. Brown博士说：“有效的生物标记将能够帮助我们了解鲁盖瑞氏症的病理过程，同时提高我们估量治疗效果的能力。”Brown是Prize4Life科学委员会成员，同时还是Day Neuromuscular Research Laboratory创始人兼董事、马萨诸塞州综合医院Muscular Dystrophy Association Clinic主任以及哈佛医学院神经病学教授。他补充说：“这一生物标记将能够加速药物发现进程，极大的缩短ALS治疗实验上所需的时间和费用。”

InnoCentive首席营销官兼全球市场副总裁Ali Hussein说：“我们很荣幸能够和Prize4Life一道加速对ALS的研究，他们将利用我们由超过110,000位科学家组成的问题解决团队。”Hussein补充说：“我们的网络对于研究机构来说，是与商业机构分享突破，并由后者将这些突破推向市场的最快和最有效方式。”Hussein说：“Prize4Life已将这一挑战发布在InnoCentive的网站上。他们认识到这是一个获取众多想法和科学途径，从而快速解决这一严重疾病的有效方式。”

有意提交生物标记方案的研究者和科学家们必须在InnoCentive网站上注册，其网站地址为 www.innocentive.com 。

关于Prize4Life

Prize4Life是一个结果导向的非盈利组织，意在通过向能够解决阻碍有效疗法发现关键技术问题的科学家提供高额奖赏，从而加速ALS (鲁盖瑞氏症) 研究。有关Prize4Life的更多信息或向Prize4Lift进行捐赠，请访问 www.prize4life.org 。

关于 InnoCentive

InnoCentive在线论坛开创先河，让世界级的科学家和科技企业在全球科学社区展开协作，找到应对复杂挑战的创新解决方案。使用其服务的企业包括，陶氏益农公司、礼来公司、宝洁公司等。这些科技企业投入数十亿美元开展研发，在InnoCentive网站隐秘发布科学问题，由超过175个国家的110,000多名科学家和科研机构解决。如果提交了最佳解决方案，能完美地达到InnoCentive的挑战要求，科学家将得到奖金，数额高达10万美元甚至更多。

如欲了解更多信息，或注册成为InnoCentive解决者，请访问InnoCentive网站：www.innocentive.com。

多媒体信息：http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5272394

联系方式：InnoCentive Ali Hussein, 首席营销官兼副总裁 全球市场 978-482-3366 或者 InnoCentive媒体联系 Tara Bal, 510-226-6780转 162 innocentive-pr@e21corp.com

(BW)(MA-INNOCENTIVE) InnoCentive Posts $1 Million Seeker Challenge for Biomarker Discovery

Objective is to Find a Biomarker for Amyotrophic Lateral Sclerosis (ALS)

ANDOVER, Mass.--(BUSINESS WIRE)--Nov. 13, 2006--

InnoCentive announced today that Prize4Life, Inc., a non-profit organization founded to accelerate Lou Gehrig's disease research, has offered a $1 million incentive to help advance the treatment for Amyotrophic Lateral Sclerosis. "This important challenge, identifying an ALS 'biomarker,' is an effort to identify a specific measurement for the disease that can aid in detection and response to therapy," said Jill A. Panetta, Ph.D., InnoCentive's Chief Scientific Officer.

"Valid biomarkers will enhance our understanding of the pathological process in ALS and our ability to gauge treatment efficacy," said Robert H. Brown, M.D., D.Phil. Brown is a member of the Prize4Life Scientific Board, as well as founder and director of the Day Neuromuscular Research Laboratory, director of the Muscular Dystrophy Association Clinic at Massachusetts General Hospital, and professor of neurology at Harvard Medical School. Brown added, "Such markers can potentially speed up drug discovery protocols and substantially shorten time and expense for treatment trials in ALS."

"We are honored to partner with Prize4Life to accelerate ALS research allowing them to tap into our problem solving community of more than 110,000 scientists," said Ali Hussein, InnoCentive's chief marketing officer and vice president global markets. "Our network is the fastest and most efficient way for research institutions to share their breakthroughs with the business communities who can develop these discoveries for the marketplace," added Hussein. "Prize4Life posted this challenge on the InnoCentive Web site, recognizing that this approach is an efficient way in which to gather a wide diversity of ideas and scientific approaches in hopes of quickly solving this significant disease," said Hussein.

Researchers and scientists interested in offering a solution for the biomarker challenges must register on InnoCentive's Web site, www.innocentive.com .

About Prize4Life

Prize4Life is a results-oriented nonprofit founded to accelerate ALS (Lou Gehrig's disease) research by offering substantial prizes to scientists who solve the most critical scientific problems preventing the discovery of an effective ALS treatment. For additional information on Prize4Life or to donate, please visit www.prize4life.org .

About InnoCentive

InnoCentive is the first online forum that allows world-class scientists and science-based companies to collaborate in a global scientific community to achieve innovative solutions to complex challenges. Companies including Dow AgroSciences, Eli Lilly and Company, Procter & Gamble and others, which collectively spend billions of dollars on R&D, post scientific problems confidentially on the InnoCentive Web site where over 110,000 scientists and scientific organizations in more than 175 countries can solve them. Scientists who deliver solutions that best meet InnoCentive's challenge requirements receive financial awards ranging up to and over $100,000.

To learn more and to register as an InnoCentive Solver, visit the InnoCentive Web site at www.innocentive.com.

MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5272394

CONTACT: InnoCentive Ali Hussein, Chief Marketing Officer, Vice President Global Markets, 978-482-3366 or Media Contact for InnoCentive Tara Bal, 510-226-6780 ext. 162 innocentive-pr@e21corp.com